Suppr超能文献

治疗甲状腺功能减退症并非总是易事:何时治疗亚临床甲状腺功能减退症、老年人的促甲状腺激素目标以及左甲状腺素单一疗法的替代方案。

Treating hypothyroidism is not always easy: When to treat subclinical hypothyroidism, TSH goals in the elderly, and alternatives to levothyroxine monotherapy.

作者信息

Ross Douglas S

机构信息

Endocrine Division, Massachusetts General Hospital, and Harvard Medical School, Boston, Massachusetts, USA.

出版信息

J Intern Med. 2022 Feb;291(2):128-140. doi: 10.1111/joim.13410. Epub 2021 Nov 11.

Abstract

The majority of patients with hypothyroidism feel better when levothyroxine treatment restores thyroid-stimulating hormone (TSH) concentrations to normal. Increasingly, a significant minority of patients remain symptomatic and are dissatisfied with their treatment. Overzealous treatment of symptomatic patients with subclinical hypothyroidism may contribute to dissatisfaction among hypothyroidism patients, as potential hypothyroid symptoms in patients with minimal hypothyroidism rarely respond to treatment. Thyroid hormone prescriptions have increased by 30% in the United States in the last decade. The diagnosis of subclinical hypothyroidism should be confirmed by repeat thyroid function tests ideally obtained at least 2 months later, as 62% of elevated TSH levels may revert to normal spontaneously. Generally, treatment is not necessary unless the TSH exceeds 7.0-10 mIU/L. In double-blinded randomized controlled trials, treatment does not improve symptoms or cognitive function if the TSH is less than 10 mIU/L. While cardiovascular events may be reduced in patients under age 65 with subclinical hypothyroidism who are treated with levothyroxine, treatment may be harmful in elderly patients with subclinical hypothyroidism. TSH goals are age dependent, with a 97.5 percentile (upper limit of normal) of 3.6 mIU/L for patients under age 40, and 7.5 mIU/L for patients over age 80. In some hypothyroid patients who are dissatisfied with treatment, especially those with a polymorphism in type 2 deiodinase, combined treatment with levothyroxine and liothyronine may be preferred.

摘要

大多数甲状腺功能减退患者在左甲状腺素治疗将促甲状腺激素(TSH)浓度恢复至正常水平后感觉好转。越来越多的少数患者仍有症状且对治疗不满意。对亚临床甲状腺功能减退的有症状患者过度治疗可能导致甲状腺功能减退患者的不满,因为轻度甲状腺功能减退患者潜在的甲状腺功能减退症状很少对治疗有反应。在过去十年中,美国甲状腺激素处方增加了30%。亚临床甲状腺功能减退的诊断应通过至少2个月后重复进行的甲状腺功能测试来确认,因为62%的TSH水平升高可能会自发恢复正常。一般来说,除非TSH超过7.0 - 10 mIU/L,否则无需治疗。在双盲随机对照试验中,如果TSH低于10 mIU/L,治疗并不能改善症状或认知功能。虽然左甲状腺素治疗可能会降低65岁以下亚临床甲状腺功能减退患者的心血管事件发生率,但对老年亚临床甲状腺功能减退患者治疗可能有害。TSH目标值因年龄而异,40岁以下患者的第97.5百分位数(正常上限)为3.6 mIU/L,80岁以上患者为7.5 mIU/L。在一些对治疗不满意的甲状腺功能减退患者中,尤其是那些2型脱碘酶存在多态性的患者,左甲状腺素和碘塞罗宁联合治疗可能更受青睐。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验